For a study, researchers sought to evaluate the effectiveness and tolerability of a face SPF50+ sunscreen comprising extracts of Myrtus communis and Celastrol after 8 weeks of usage and the advantages on the fall recurrence of acne “Post-Sun Exposure” (P-S.E.).
They included and examined 45 mild to severe acne patients. The treatment was used at least twice a day for eight summer weeks to gauge tolerance and effectiveness (D29/D57), after which the subjects ceased using it for a month to gauge how much acne P-S.E recurrence was limited (D85).
The tolerance was rated as excellent by the investigators. The effectiveness of the anti-imperfections treatment was shown by the lesions counting [for example, a substantial decrease in inflammatory lesions (P< .001) at D57 (-30.6%)]; the subjects’ evaluation of their acne (e.g., an improvement in their acne of 72.1% at D57), the quality of life (QoL) questionnaire (Cardiff Acne Disability Index/CADI, Dermatology Life Quality Index/DLQI, and Children Dermatology Life Quality Index/CDLQI) [e.g., a significant improvement (P< .05) of the CADI score at D57 (-46,0%); a cosmetic acceptance questionnaire [anti-imperfections efficacy for 86.0% and reduction of the blemishes for 83.7%]. Furthermore, a substantial reduction in inflammatory (-40.3%), noninflammatory (-16.0%), and overall acne lesions (-28.4%) was seen at D85 (P<.001). Additionally, 93.8% of the individuals thought their spots were less or equally noticeable, and 71.9% noted fewer flaws than typical during the fall time.
The Myrtus communis and Celastrol-enriched plant cell culture extracts in the SPF 50+ sunscreen were well accepted, effective in reducing acne, and also helped to reduce the recurrence of lesions P-S.E.